Industries > Pharma > Global Ophthalmic Drugs Market Forecast 2017-2027

Global Ophthalmic Drugs Market Forecast 2017-2027

Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

PUBLISHED: 14 June 2017
PAGES: 306
PRODUCT CODE: PHA0202
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0202 Categories: , Tag:

The global ophthalmic drugs market is expected to grow at a CAGR of 4.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.6% from 2017-2027. The market is estimated at $23bn in 2016 and $28.1bn in 2021. In 2016, the retinal disorder drugs submarket held 40% of the share in this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 306-page report you will receive 125 tables and 113 figures – all unavailable elsewhere.

The 306-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Ophthalmic Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecasts to 2027 for the global ophthalmic drugs market by the leading submarkets:
– Retinal Disorder Drugs
– Allergic, Inflammatory & Infective Drugs
– Glaucoma Drugs
– Dry Eye Drugs
– Other Ophthalmic Drugs

Global Ophthalmic Drugs Market Forecast 2017-2027

• This report includes revenue forecasts to 2027 for the following ophthalmic drugs:
– Eylea
– Lucentis
– Avastin
– Visudyne
– Jetrea
– Pataday
– Vigamox
– Patanol
– TobraDex
– Cravit
– AzaSite
– Acular
– Lumigan and Ganfort
– Xalatan/Xalacom
– Travatan/Travatan Z and DuoTrav
– Alphagan/Alphagan P and Combigan
– Azopt
– Trusopt
– Zioptan
– Cosopt
– Tapros/Taflotan
– Restasis
– Refresh
– Hyalein
– Diquas

• This report provides individual revenue forecasts to 2027 for these national markets:
– The US
– Japan
– EU5: Germany, France, the UK, Spain, Italy
– Russia
– China
– India
– Brazil
– Rest of the World

• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
– Novartis
– Regeneron
– Allergan
– Roche
– Valeant
– Santen
– Bayer
– Pfizer
– Senju

Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories